Elevance Health Inc. (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.Elevance Health shares rose 1.8% to $397.20 in pre-market trading.These analysts made changes to their price targets on Elevance Health following earnings announcement.
Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.
Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.
Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.
